News
2020.12.14
Sai Life Sciences releases its first Sustainability Report
• Developed as per the Global Reporting Initiative (GRI) standards • Highlights the various sustainable choices embraced by the company in steering its journey on a sustainable path Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO/ CDMO), today announced the release of its first Sustainability Report as per […]
Read more
2020.11.20
Sai Life Sciences opens representative office in Tokyo, Japan
Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), announced the opening of its representative office in Tokyo, Japan. The new office will serve as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region. A seasoned industry […]
Read more
2020.10.26
Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus
Commences construction of new 75,000 sq. ft. facility in Hyderabad Augmenting India team to 170 biologists Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility […]
Read more
2020.10.23
Sai Life Sciences introduces Green Chemistry Awards
With the purpose of celebrating and recognizing teams and projects that demonstrate notable work in Green Chemistry, Sai Life Sciences instituted the ‘Green Chemistry Awards’ earlier this year. Using an internally developed computational model, projects were assessed on their ‘Greenness Index’ that is a composite of several attributes across atom & mass efficiency, e-factor, water […]
Read more
2020.10.23
Comprehensive ICH-M7 assessments for starting materials, intermediates, and final API
Sai Life Sciences offers comprehensive ICH-M7 services to help assess the potential risks of our customers’ starting materials, intermediates, and final API for mutagenicity assessment. As mandated in the ICH M7 guidelines, pharmaceutical companies are now required to assess, identify, and categorize their starting materials, intermediates and final API routes of synthesis and resulting impurities […]
Read more
2020.09.10
Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA
Sai Life Sciences today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA. Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities include the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and […]
Read more